Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
Copyright © 2021 Massachusetts Medical Society..
BACKGROUND: Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α).
METHODS: In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan.
RESULTS: After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl).
CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.).
| Errataetall: |
CommentIn: N Engl J Med. 2021 Nov 25;385(22):2090-2091. - PMID 34818485 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 385(2021), 22 vom: 25. Nov., Seite 2036-2046 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jonasch, Eric [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7K28NB895L |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 16.07.2022 published: Print ClinicalTrials.gov: NCT03401788 CommentIn: N Engl J Med. 2021 Nov 25;385(22):2090-2091. - PMID 34818485 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2103425 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333556828 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333556828 | ||
| 003 | DE-627 | ||
| 005 | 20231225221904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2103425 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333556828 | ||
| 035 | |a (NLM)34818478 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jonasch, Eric |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03401788 | ||
| 500 | |a CommentIn: N Engl J Med. 2021 Nov 25;385(22):2090-2091. - PMID 34818485 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α) | ||
| 520 | |a METHODS: In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan | ||
| 520 | |a RESULTS: After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl) | ||
| 520 | |a CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Basic Helix-Loop-Helix Transcription Factors |2 NLM | |
| 650 | 7 | |a Indenes |2 NLM | |
| 650 | 7 | |a belzutifan |2 NLM | |
| 650 | 7 | |a 7K28NB895L |2 NLM | |
| 700 | 1 | |a Donskov, Frede |e verfasserin |4 aut | |
| 700 | 1 | |a Iliopoulos, Othon |e verfasserin |4 aut | |
| 700 | 1 | |a Rathmell, W Kimryn |e verfasserin |4 aut | |
| 700 | 1 | |a Narayan, Vivek K |e verfasserin |4 aut | |
| 700 | 1 | |a Maughan, Benjamin L |e verfasserin |4 aut | |
| 700 | 1 | |a Oudard, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Else, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Maranchie, Jodi K |e verfasserin |4 aut | |
| 700 | 1 | |a Welsh, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Thamake, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Eric K |e verfasserin |4 aut | |
| 700 | 1 | |a Perini, Rodolfo F |e verfasserin |4 aut | |
| 700 | 1 | |a Linehan, W Marston |e verfasserin |4 aut | |
| 700 | 1 | |a Srinivasan, Ramaprasad |e verfasserin |4 aut | |
| 700 | 0 | |a MK-6482-004 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Jonasch, Eric |e investigator |4 oth | |
| 700 | 1 | |a Zurita-Saavedra, Amado J |e investigator |4 oth | |
| 700 | 1 | |a Shah, Amishi |e investigator |4 oth | |
| 700 | 1 | |a Gao, Jianjun |e investigator |4 oth | |
| 700 | 1 | |a Araujo, John C |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Matthew T |e investigator |4 oth | |
| 700 | 1 | |a Tannir, Nizar |e investigator |4 oth | |
| 700 | 1 | |a Goswami, Sangeeta |e investigator |4 oth | |
| 700 | 1 | |a Lim, Zita |e investigator |4 oth | |
| 700 | 1 | |a Cotton, Irene |e investigator |4 oth | |
| 700 | 1 | |a Pham, Oanh |e investigator |4 oth | |
| 700 | 1 | |a Shaw, Leah |e investigator |4 oth | |
| 700 | 1 | |a Rathmell, Kimryn |e investigator |4 oth | |
| 700 | 1 | |a Beckerman, Kathryn Eby |e investigator |4 oth | |
| 700 | 1 | |a Ancell, Kristin Kathleen |e investigator |4 oth | |
| 700 | 1 | |a Wallace, Deborah E |e investigator |4 oth | |
| 700 | 1 | |a Srinivasan, Ramaprasad |e investigator |4 oth | |
| 700 | 1 | |a Hawkins, Deborah Kay |e investigator |4 oth | |
| 700 | 1 | |a Davis, Nancy B |e investigator |4 oth | |
| 700 | 1 | |a Kaiser, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Schaffer, Kerry |e investigator |4 oth | |
| 700 | 1 | |a Linehan, W Marston |e investigator |4 oth | |
| 700 | 1 | |a Chittiboina, Prashant |e investigator |4 oth | |
| 700 | 1 | |a Zaghloul, Kareem |e investigator |4 oth | |
| 700 | 1 | |a Friend, Julia |e investigator |4 oth | |
| 700 | 1 | |a Choyke, Peter |e investigator |4 oth | |
| 700 | 1 | |a Chew, Emily |e investigator |4 oth | |
| 700 | 1 | |a Wiley, Henry |e investigator |4 oth | |
| 700 | 1 | |a Elinoff, Jason |e investigator |4 oth | |
| 700 | 1 | |a Ball, Mark |e investigator |4 oth | |
| 700 | 1 | |a Romero, Vladimir Valera |e investigator |4 oth | |
| 700 | 1 | |a Bottaro, Donald P |e investigator |4 oth | |
| 700 | 1 | |a Vocke, Cathy |e investigator |4 oth | |
| 700 | 1 | |a Purcell, Erin |e investigator |4 oth | |
| 700 | 1 | |a Al Harthy, Munjid |e investigator |4 oth | |
| 700 | 1 | |a Iliopoulos, Othon |e investigator |4 oth | |
| 700 | 1 | |a Leger, Paul |e investigator |4 oth | |
| 700 | 1 | |a Mac, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Gurski, Carol |e investigator |4 oth | |
| 700 | 1 | |a Lee, Richard |e investigator |4 oth | |
| 700 | 1 | |a Markt, Denise A |e investigator |4 oth | |
| 700 | 1 | |a Meneely, Erika |e investigator |4 oth | |
| 700 | 1 | |a Michaelson, Dror |e investigator |4 oth | |
| 700 | 1 | |a Olivier, Kara |e investigator |4 oth | |
| 700 | 1 | |a Saylor, Philip |e investigator |4 oth | |
| 700 | 1 | |a Smith, Matthew |e investigator |4 oth | |
| 700 | 1 | |a Maughan, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Agarwal, Neeraj |e investigator |4 oth | |
| 700 | 1 | |a Phunrab, Tenzin |e investigator |4 oth | |
| 700 | 1 | |a Greenberg, Samantha |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Sumati |e investigator |4 oth | |
| 700 | 1 | |a Thorley, Jared |e investigator |4 oth | |
| 700 | 1 | |a Batten, Julia |e investigator |4 oth | |
| 700 | 1 | |a Lowrance, Will |e investigator |4 oth | |
| 700 | 1 | |a O'Neil, Brock |e investigator |4 oth | |
| 700 | 1 | |a Dechet, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Else, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Alva, Ajjai |e investigator |4 oth | |
| 700 | 1 | |a Demirci, Hakan |e investigator |4 oth | |
| 700 | 1 | |a Hafez, Khaled |e investigator |4 oth | |
| 700 | 1 | |a Osborne, Jenae |e investigator |4 oth | |
| 700 | 1 | |a Quinonez, Shane |e investigator |4 oth | |
| 700 | 1 | |a Stoffel, Elena |e investigator |4 oth | |
| 700 | 1 | |a Maranchie, Jodi |e investigator |4 oth | |
| 700 | 1 | |a Hrebinko, Ronald |e investigator |4 oth | |
| 700 | 1 | |a Davies, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Jacobs, Bruce |e investigator |4 oth | |
| 700 | 1 | |a Bishop, Kayla |e investigator |4 oth | |
| 700 | 1 | |a Narayan, Vivek |e investigator |4 oth | |
| 700 | 1 | |a Vaughn, David |e investigator |4 oth | |
| 700 | 1 | |a Mamtani, Ronac |e investigator |4 oth | |
| 700 | 1 | |a Balzer-Haas, Naomi |e investigator |4 oth | |
| 700 | 1 | |a Nathanson, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Takvorian, Samuel |e investigator |4 oth | |
| 700 | 1 | |a Dahan, Mindy |e investigator |4 oth | |
| 700 | 1 | |a Jones, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Ciconte, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Welsh, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Maher, Eamon |e investigator |4 oth | |
| 700 | 1 | |a Eisen, Tim |e investigator |4 oth | |
| 700 | 1 | |a Denholm, Mary |e investigator |4 oth | |
| 700 | 1 | |a Fife, Kate |e investigator |4 oth | |
| 700 | 1 | |a Matakidou, Athena |e investigator |4 oth | |
| 700 | 1 | |a Donskov, Frede |e investigator |4 oth | |
| 700 | 1 | |a Iversen, Ane |e investigator |4 oth | |
| 700 | 1 | |a Agerbaek, Mads |e investigator |4 oth | |
| 700 | 1 | |a Oudard, Stephane |e investigator |4 oth | |
| 700 | 1 | |a Thibault, Constance |e investigator |4 oth | |
| 700 | 1 | |a Vano, Yann-Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Medioni, Jacques |e investigator |4 oth | |
| 700 | 1 | |a Richard, Stephane |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 385(2021), 22 vom: 25. Nov., Seite 2036-2046 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2021 |g number:22 |g day:25 |g month:11 |g pages:2036-2046 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2103425 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2021 |e 22 |b 25 |c 11 |h 2036-2046 | ||